Abivax Announces $235.8 Million IPO
New York – October 20, 2023 – Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.
Abivax offered a total of 20,325,500 ordinary shares – consisting of 18,699,460 American depositary shares and 1,626,040 ordinary shares in certain jurisdictions outside the US – priced at $11.60 per share, with a 30-day option for the underwriters to purchase up to 3,048,825 additional ordinary and/or American depositary shares. The listing is now trading on the Nasdaq Global Market under the symbol ABVX.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has over 1,300 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.